Literature DB >> 7386229

Localization of aldosterone-producing tumours in primary aldosteronism by adrenal and renal vein catheterization.

J O Lund, M D Nielsen, J Giese, P A Gammelgaard, E Hasner, B Hesse, K H Tønnesen.   

Abstract

Regional venous plasma aldosterone concentrations were determined and assessed against concurrent arterial levels in 16 patients with primary aldosteronism. The results obtained by sampling from the left adrenal vein or the left renal vein allowed correct side prediction of the presupposed adenoma in each patient. The problems caused by intermittent secretion of aldosterone by the tumour and the importance of correct positioning of the catheter are emphasized. Repeated sampling and continuing reference to systemic, arterial aldosterone levels proved valuable.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7386229     DOI: 10.1111/j.0954-6820.1980.tb09736.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  4 in total

1.  Cosyntropin stimulation in adrenal vein testing for aldosteronoma.

Authors:  R H Noth; S L Glaser; J C Palmaz
Journal:  West J Med       Date:  1985-01

2.  Effects of insulin on kidney function and sodium excretion in healthy subjects.

Authors:  P Skøtt; O Hother-Nielsen; N E Bruun; J Giese; M D Nielsen; H Beck-Nielsen; H H Parving
Journal:  Diabetologia       Date:  1989-09       Impact factor: 10.122

3.  Effects of combined therapy with amiloride and hydrochlorothiazide on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in hypertensive patients.

Authors:  U G Svendsen; H Ibsen; S Rasmussen; A Leth; M D Nielsen; H Dige-Petersen; J Giese
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Effects of acute beta-adrenoceptor blockade with metoprolol on the renal response to dopamine in normal humans.

Authors:  N V Olsen; T Lang-Jensen; J M Hansen; I Plum; J K Thomsen; S Strandgaard; P P Leyssac
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.